Yipinhong Pharmaceutical Co Ltd banner

Yipinhong Pharmaceutical Co Ltd
SZSE:300723

Watchlist Manager
Yipinhong Pharmaceutical Co Ltd Logo
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Watchlist
Price: 34.55 CNY -3.14% Market Closed
Market Cap: ¥15.6B

EV/EBITDA

-31
Current
191%
Cheaper
vs 3-y average of 34.2

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-31
=
Enterprise Value
¥16.2B
/
EBITDA
¥-547.5m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-31
=
Enterprise Value
¥16.2B
/
EBITDA
¥-547.5m

Valuation Scenarios

Yipinhong Pharmaceutical Co Ltd is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (34.2), the stock would be worth ¥-38.01 (210% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-210%
Maximum Upside
No Upside Scenarios
Average Downside
191%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple -31 ¥34.55
0%
3-Year Average 34.2 ¥-38.01
-210%
5-Year Average 26.4 ¥-29.36
-185%
Industry Average 23.9 ¥-26.6
-177%
Country Average 28.8 ¥-32.08
-193%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥16.2B
/
Oct 2025
¥-547.5m
=
-31
Current
¥16.2B
/
Dec 2025
¥457.9m
=
35.4
Forward
¥16.2B
/
Dec 2026
¥538.8m
=
30.1
Forward
¥16.2B
/
Dec 2027
¥610.6m
=
26.6
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
15.6B CNY -31 -36.3
US
Eli Lilly and Co
NYSE:LLY
867B USD 28.4 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 16.9 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.9 20.1
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 15.6 28.1
CH
Novartis AG
SIX:NOVN
223.1B CHF 12.2 19.7
US
Merck & Co Inc
NYSE:MRK
283.6B USD 9.7 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8.2 11.2
US
Pfizer Inc
NYSE:PFE
151.6B USD 7.5 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 7.2 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Average EV/EBITDA: 50.5
Negative Multiple: -31
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.4
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.9
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
15.6
12%
1.3
CH
Novartis AG
SIX:NOVN
12.2
5%
2.4
US
Merck & Co Inc
NYSE:MRK
9.7
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.2
2%
4.1
US
Pfizer Inc
NYSE:PFE
7.5
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-9%
N/A
P/E Multiple
Earnings Growth PEG
CN
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Average P/E: 22.2
Negative Multiple: -36.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.1
25%
1.1
CH
Novartis AG
SIX:NOVN
19.7
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 5 409 companies
0th percentile
-31
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Yipinhong Pharmaceutical Co Ltd
Glance View

Market Cap
15.6B CNY
Industry
Pharmaceuticals

Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.

Intrinsic Value
8.85 CNY
Overvaluation 74%
Intrinsic Value
Price ¥34.55
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett